Shigeru Goto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shigeru Goto has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Toshiaki Nakano
Graduate Institute of Clinical Medical Sciences, Chang Gung University College of Medicine, Taoyuan 333, Taiwan
10 shared publications - King-Wah Chiu
Division of Hepato-gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 83301, Taiwan
6 shared publications - Yu-Fan Cheng
Department of Diagnostic Radiology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan
5 shared publications - Chao-Long Chen
Liver Transplantation Program, Department of Surgery, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Kaohsiung, Taiwan
4 shared publications Seigo Kitano
Department of Surgery I, Oita University, Faculty of Medicine, Oita, Japan
3 shared publicationsAtsushi Sasaki
Department of Surgery I, Oita University Faculty of Medicine, Oita, Japan
2 shared publications
Latest Publications
- Open Access
- 22 April 2017
- Published by Graphy Publications in International Journal of Surgery & Surgical Procedures
- Vol. 2 (1)
The Significance of a Nuclear Protein as a Moonlight Protein: Diagnostic and Therapeutic Potentials in Liver Transplantation
The Significance of a Nuclear Protein as a Moonlight Protein: Diagnostic and Therapeutic Potentials in Liver Transplantation
- 22 April 2017
- Published by Graphy Publications in International Journal of Surgery & Surgical Procedures
- Vol. 2 (1)
Open AccessThe Significance of a Nuclear Protein as a Moonlight Protein: Diagnostic and Therapeutic Potentials in Liver Transplantation
The Significance of a Nuclear Protein as a Moonlight Protein: Diagnostic and Therapeutic Potentials in Liver Transplantation
- 23 October 2014
- Published by Wiley in Hepatology Research
- Vol. 45 (7) , 804-813
Prolonged survival by combined treatment with granulocyte colony‐stimulating factor and dipeptidyl peptidase IV inhibitor in a rat small‐for‐size liver transplantation model
Aim: Despite the great advances and excellent outcomes of liver transplantation (LT), small‐for‐size (SFS) graft syndrome is a life‐threatening complication that remains to be overcome. In the present study, we investigated the therapeutic effect of combined treatment with granulocyte colony‐stimulating factor (G‐CSF) and a dipeptidyl peptidase IV (DPP‐IV) inhibitor on SFS liver graft syndrome.Methods: The transplantation of small‐sized Lewis donor livers into green fluorescent protein (GFP) transgenic Wistar rats was performed and the recipients were randomly assigned to one of four groups (without treatment, DPP‐IV inhibitor treatment, G‐CSF treatment and G‐CSF/DPP‐IV inhibitor combination). Recombinant human G‐CSF was injected s.c. at a dose of 2 μg/kg per day starting 5 days prior to transplantation. G‐CSF was combined with the p.o. administration of a DPP‐IV inhibitor (2 mg/kg per day) after transplantation until the end of the observation period.Results: The post‐transplant survival and liver function of rats treated with G‐CSF/DPP‐IV inhibitor combination therapy were significantly improved with an increased number of recipient‐derived GFP positive cells into the liver grafts. A confocal microscopy study showed cytokeratin (CK)‐18 and GFP positive hepatic progenitor cells in the parenchyma of the liver allografts. Untreated rats and rats treated with either G‐CSF or DPP‐IV inhibitor did not exhibit the prolonged survival and had less GFP and CK‐18 positive cells in the liver grafts after SFS LT.Conclusion: Our results suggest that combined treatment with G‐CSF and DPP‐IV inhibitor may synergistically induce migration and differentiation of recipient‐derived stem cells into the hepatic progenitor cells, resulting in the amelioration of SFS liver graft syndrome.
- 23 October 2014
- Published by Wiley in Hepatology Research
- Vol. 45 (7) , 804-813
Prolonged survival by combined treatment with granulocyte colony‐stimulating factor and dipeptidyl peptidase IV inhibitor in a rat small‐for‐size liver transplantation model
Aim: Despite the great advances and excellent outcomes of liver transplantation (LT), small‐for‐size (SFS) graft syndrome is a life‐threatening complication that remains to be overcome. In the present study, we investigated the therapeutic effect of combined treatment with granulocyte colony‐stimulating factor (G‐CSF) and a dipeptidyl peptidase IV (DPP‐IV) inhibitor on SFS liver graft syndrome.Methods: The transplantation of small‐sized Lewis donor livers into green fluorescent protein (GFP) transgenic Wistar rats was performed and the recipients were randomly assigned to one of four groups (without treatment, DPP‐IV inhibitor treatment, G‐CSF treatment and G‐CSF/DPP‐IV inhibitor combination). Recombinant human G‐CSF was injected s.c. at a dose of 2 μg/kg per day starting 5 days prior to transplantation. G‐CSF was combined with the p.o. administration of a DPP‐IV inhibitor (2 mg/kg per day) after transplantation until the end of the observation period.Results: The post‐transplant survival and liver function of rats treated with G‐CSF/DPP‐IV inhibitor combination therapy were significantly improved with an increased number of recipient‐derived GFP positive cells into the liver grafts. A confocal microscopy study showed cytokeratin (CK)‐18 and GFP positive hepatic progenitor cells in the parenchyma of the liver allografts. Untreated rats and rats treated with either G‐CSF or DPP‐IV inhibitor did not exhibit the prolonged survival and had less GFP and CK‐18 positive cells in the liver grafts after SFS LT.Conclusion: Our results suggest that combined treatment with G‐CSF and DPP‐IV inhibitor may synergistically induce migration and differentiation of recipient‐derived stem cells into the hepatic progenitor cells, resulting in the amelioration of SFS liver graft syndrome.
- 1 April 2014
- Published by Elsevier in Transplantation Proceedings
- Vol. 46 (3) , 894-896
Elevation of C-Reactive Protein Level and Its Correlation With Psychiatric Comorbidities in Recipients After Liver Transplantation
- 1 April 2014
- Published by Elsevier in Transplantation Proceedings
- Vol. 46 (3) , 894-896
Elevation of C-Reactive Protein Level and Its Correlation With Psychiatric Comorbidities in Recipients After Liver Transplantation
- Open Access
- 23 April 2013
- Published by Springer Nature in Transplantation Research
- Vol. 2 (1) , 6
Biological interactions of CYP2C19 genotypes with CYP3A4*18, CYP3A5*3, and MDR1-3435 in living donor liver transplantation recipients
Polymorphisms in CYP2C19 are related to the metabolic oxidation of drugs to varying degrees. The CYP3A4*18, CYP3A5*3, and MDR1-3435 variant alleles are very important, particularly in tacrolimus metabolism in organ transplant rejection.
- 23 April 2013
- Published by Springer Nature in Transplantation Research
- Vol. 2 (1) , 6
Open AccessBiological interactions of CYP2C19 genotypes with CYP3A4*18, CYP3A5*3, and MDR1-3435 in living donor liver transplantation recipients
Polymorphisms in CYP2C19 are related to the metabolic oxidation of drugs to varying degrees. The CYP3A4*18, CYP3A5*3, and MDR1-3435 variant alleles are very important, particularly in tacrolimus metabolism in organ transplant rejection.
- Open Access
- 14 April 2013
- Published by Wiley in Journal of Immunology Research
- Vol. 2013, 1-9
Nuclear Antigens and Auto/Alloantibody Responses: Friend or Foe in Transplant Immunology
In addition to cellular immune responses, humoral immune responses, mediated by natural antibodies, autoantibodies, and alloantibodies, have increasingly been recognized as causes of organ transplant rejection. In our previous studies, we have demonstrated the induction of antinuclear antibodies against histone H1 and high-mobility group box 1 (HMGB1), in both experimental and clinical liver transplant tolerance. The active induction of antinuclear antibodies is usually an undesirable phenomenon, but it is often observed after liver transplantation. However, the release of nuclear antigens and its suppression by neutralizing antibodies are proposed to be important in the initiation and regulation of immune responses. In this review article, we summarize the current understanding of nuclear antigens and corresponding antinuclear regulatory antibodies (Abregs) on infection, injury, inflammation, transplant rejection, and tolerance induction and discuss the significance of nuclear antigens as diagnostic and therapeutic targets.
- 14 April 2013
- Published by Wiley in Journal of Immunology Research
- Vol. 2013, 1-9
Open AccessNuclear Antigens and Auto/Alloantibody Responses: Friend or Foe in Transplant Immunology
In addition to cellular immune responses, humoral immune responses, mediated by natural antibodies, autoantibodies, and alloantibodies, have increasingly been recognized as causes of organ transplant rejection. In our previous studies, we have demonstrated the induction of antinuclear antibodies against histone H1 and high-mobility group box 1 (HMGB1), in both experimental and clinical liver transplant tolerance. The active induction of antinuclear antibodies is usually an undesirable phenomenon, but it is often observed after liver transplantation. However, the release of nuclear antigens and its suppression by neutralizing antibodies are proposed to be important in the initiation and regulation of immune responses. In this review article, we summarize the current understanding of nuclear antigens and corresponding antinuclear regulatory antibodies (Abregs) on infection, injury, inflammation, transplant rejection, and tolerance induction and discuss the significance of nuclear antigens as diagnostic and therapeutic targets.
- 1 May 2012
- Published by Update Medical Publishing in Hepatogastroenterology
- Vol. 59 (115) , 805-8
Western blotting analysis for quantitative detection of CYP2C19 expression in liver tissues in the setting of living donor liver transplantation.
The cytochrome P450 (CYP) drug-metabolizing enzymes play an important role in cellular metabolism. Therapeutic failure or drug toxicity in the period after liver transplantation (LT) is influenced by the drug metabolizing capacity of the graft. The expression levels of CYP2C19 enzyme are often used as an indicator of the functioning of the CYP system. The aim of the present study was to assess the CYP2C19 protein expression in the setting of living donor liver transplantation (LDLT) by using western blotting analysis. We performed CYP2C19 genotyping of liver biopsy samples obtained from 24 donors and 8 recipients each in the pre- and post-LT periods, after which we analyzed the CYP enzyme activity by using western blotting analysis. The CYP2C19/β-actin ratio, which was an indicator of CYP expression, was 61.75% (23-100%) in donors, 59.13% (15-100%) in pre-LT recipients and 46.71% (12-67%) in post-LT recipients (p>0.05). The CYP2C19 expression levels associated with different genotypes were as follows: homozygous extensive metabolizers (HomEMs; n=24), 56.63±24.74%; heterozygous extensive metabolizers (HetEMs; n=15), 63.0±25.14% and poor metabolizers (PMs; n=1), 82.0% (p>0.05). Western blotting analysis showed low CYP2C19 protein expression not only in samples from the pre- and post-LT recipients but also from the donors.
- 1 May 2012
- Published by Update Medical Publishing in Hepatogastroenterology
- Vol. 59 (115) , 805-8
Western blotting analysis for quantitative detection of CYP2C19 expression in liver tissues in the setting of living donor liver transplantation.
The cytochrome P450 (CYP) drug-metabolizing enzymes play an important role in cellular metabolism. Therapeutic failure or drug toxicity in the period after liver transplantation (LT) is influenced by the drug metabolizing capacity of the graft. The expression levels of CYP2C19 enzyme are often used as an indicator of the functioning of the CYP system. The aim of the present study was to assess the CYP2C19 protein expression in the setting of living donor liver transplantation (LDLT) by using western blotting analysis. We performed CYP2C19 genotyping of liver biopsy samples obtained from 24 donors and 8 recipients each in the pre- and post-LT periods, after which we analyzed the CYP enzyme activity by using western blotting analysis. The CYP2C19/β-actin ratio, which was an indicator of CYP expression, was 61.75% (23-100%) in donors, 59.13% (15-100%) in pre-LT recipients and 46.71% (12-67%) in post-LT recipients (p>0.05). The CYP2C19 expression levels associated with different genotypes were as follows: homozygous extensive metabolizers (HomEMs; n=24), 56.63±24.74%; heterozygous extensive metabolizers (HetEMs; n=15), 63.0±25.14% and poor metabolizers (PMs; n=1), 82.0% (p>0.05). Western blotting analysis showed low CYP2C19 protein expression not only in samples from the pre- and post-LT recipients but also from the donors.
- Open Access
- 25 May 2011
- Published by Springer Nature in BMC Immunology
- Vol. 12 (1) , 32
Adaptor protein Shc acts as an immune-regulator for the LPS-stimulated maturation of bone marrow-derived dendritic cells
The Shc isoforms is known to mediate immune responses and has been indicated as a negative regulator of autoimmunity and lymphocyte activation. We aimed to evaluate the immune-regulatory role of Shc in rat bone marrow-derived DCs in the maturation process triggered by LPS.
- 25 May 2011
- Published by Springer Nature in BMC Immunology
- Vol. 12 (1) , 32
Open AccessAdaptor protein Shc acts as an immune-regulator for the LPS-stimulated maturation of bone marrow-derived dendritic cells
The Shc isoforms is known to mediate immune responses and has been indicated as a negative regulator of autoimmunity and lymphocyte activation. We aimed to evaluate the immune-regulatory role of Shc in rat bone marrow-derived DCs in the maturation process triggered by LPS.
- 25 December 2010
- Vol. 15 (4) , 38-43
Influence of CYP2C19 genotypes on graft pathological findings and postoperative liver function in recipients after living-donor liver transplantation.
New graft cytochrome P450 2C19 (CYP2C19) should have different characteristics after living-donor liver transplantation (LDLT). We prospectively investigated the influence of genotypes of CYP2C19 in liver graft pathological finding (GPF) and postoperative liver function (POLF) of recipients after LDLT. Among 60 consecutive patients who underwent LDLT, 36 recipients developed sudden-onset abnormal liver function and required liver biopsy, while the remaining 24 recipients did not require biopsy. LDLT recipient blood samples were genotyped for CYP2C19 variants, and recipients were categorized as homozygous extensive metabolizers (HomEM), heterozygous extensive metabolizers (HetEM), and poor metabolizers (PM). The acute rejection rate was 15.0% (9/60). There were 4 characteristics of GPF when abnormal POLF occurred. Logistic regression analysis showed that the risk estimate of abnormal POLF was 26.7 times higher for LDLT recipients with the CYP2C19 HomEM genotype as compared to the PM genotype, and 5.0 times higher for LDLT recipients with the HomEM genotype as compared to the HetEM genotype. A linear trend relationship was found between the incidence of abnormal POLF and the CYP2C19 genotype. These results suggest that the speed of drug metabolism as characterized by the CYP2C19 genotype (HomEM > HetEM > PM) may affect the outcome after LDLT; thus, CYP2C19 genotyping may be valuable for predicting abnormal POLF with different GPF after LDLT.
- 25 December 2010
- Vol. 15 (4) , 38-43
Influence of CYP2C19 genotypes on graft pathological findings and postoperative liver function in recipients after living-donor liver transplantation.
New graft cytochrome P450 2C19 (CYP2C19) should have different characteristics after living-donor liver transplantation (LDLT). We prospectively investigated the influence of genotypes of CYP2C19 in liver graft pathological finding (GPF) and postoperative liver function (POLF) of recipients after LDLT. Among 60 consecutive patients who underwent LDLT, 36 recipients developed sudden-onset abnormal liver function and required liver biopsy, while the remaining 24 recipients did not require biopsy. LDLT recipient blood samples were genotyped for CYP2C19 variants, and recipients were categorized as homozygous extensive metabolizers (HomEM), heterozygous extensive metabolizers (HetEM), and poor metabolizers (PM). The acute rejection rate was 15.0% (9/60). There were 4 characteristics of GPF when abnormal POLF occurred. Logistic regression analysis showed that the risk estimate of abnormal POLF was 26.7 times higher for LDLT recipients with the CYP2C19 HomEM genotype as compared to the PM genotype, and 5.0 times higher for LDLT recipients with the HomEM genotype as compared to the HetEM genotype. A linear trend relationship was found between the incidence of abnormal POLF and the CYP2C19 genotype. These results suggest that the speed of drug metabolism as characterized by the CYP2C19 genotype (HomEM > HetEM > PM) may affect the outcome after LDLT; thus, CYP2C19 genotyping may be valuable for predicting abnormal POLF with different GPF after LDLT.
- Open Access
- 24 April 2008
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 152 (3) , 576-584
The role of a nuclear protein, histone H1, on signalling pathways for the maturation of dendritic cells
We have demonstrated previously that liver allograft tolerance is associated with the immunosuppressive activity of anti-histone H1 autoreactive antibodies induced in the serum of liver transplantation. Furthermore, we and others have shown that nuclear proteins such as histone H1 and high mobility group box 1 play an important role in maturation of dendritic cells (DCs), although the precise mechanisms are still unknown. In the present study, we focus upon the significance of histone H1 on DCs in terms of the intracellular signalling pathway of DCs. Our immunostaining and immunoblot studies demonstrated that histone H1 was detected in cytoplasm and culture supernatants upon the activation of DCs. Histone H1 blockage by anti-histone H1 antibody down-regulated the intracellular activation of mitogen-activated protein kinases (MAPKs) (p38) and IκBα of DCs, and inhibited DC activity in the proliferation of CD4+ T cells. On the other hand, the addition of histone H1 without endotoxin stimulation up-regulated major histocompatibility complex class II, the CD80 and CD86 surface markers of DCs and the activation of MAPKs (p38 and extracellular-regulated kinase 1/2) and IκBα. These results suggest that the translocation of histone H1 from nuclei to cytoplasm and the release of their own histone H1 are necessary for the maturation of DCs and the activation for T lymphocytes.
- 24 April 2008
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 152 (3) , 576-584
Open AccessThe role of a nuclear protein, histone H1, on signalling pathways for the maturation of dendritic cells
We have demonstrated previously that liver allograft tolerance is associated with the immunosuppressive activity of anti-histone H1 autoreactive antibodies induced in the serum of liver transplantation. Furthermore, we and others have shown that nuclear proteins such as histone H1 and high mobility group box 1 play an important role in maturation of dendritic cells (DCs), although the precise mechanisms are still unknown. In the present study, we focus upon the significance of histone H1 on DCs in terms of the intracellular signalling pathway of DCs. Our immunostaining and immunoblot studies demonstrated that histone H1 was detected in cytoplasm and culture supernatants upon the activation of DCs. Histone H1 blockage by anti-histone H1 antibody down-regulated the intracellular activation of mitogen-activated protein kinases (MAPKs) (p38) and IκBα of DCs, and inhibited DC activity in the proliferation of CD4+ T cells. On the other hand, the addition of histone H1 without endotoxin stimulation up-regulated major histocompatibility complex class II, the CD80 and CD86 surface markers of DCs and the activation of MAPKs (p38 and extracellular-regulated kinase 1/2) and IκBα. These results suggest that the translocation of histone H1 from nuclei to cytoplasm and the release of their own histone H1 are necessary for the maturation of DCs and the activation for T lymphocytes.